BJH - volume 16, issue 1, february 2025
C. Graux MD, PhD
In previous ASH meetings, the focus has long been on novel drugs for R/R ALL such as blinatumomab, inotuzumab, and CAR-T. Today, we have exciting information on how the incorporation/combination of these novel agents in the first-line treatment of ALL patients (pts) could reduce the incidence of relapse and prolong the survival of these pts, thus challenging the indication of hematopoietic stem cell transplantation (HSCT) in first complete remission (CR).
(BELG J HEMATOL 2025;16(1):31–3)
Read moreBJH - volume 12, issue 5, september 2021
C. Graux MD, PhD
The EHA congress is not only the opportunity to present or update the results of clinical trials, but it is also the occasion to present some fundamental research and to discuss certain themes that allow us rethinking the overall treatment strategy and monitoring of haematologic diseases.
(BELG J HEMATOL 2021;12(5):207-10)
Read moreBJH - volume 11, issue 4, june 2020
B. Vandenhove PhD student, L. Canti PhD student, H. Schoemans MD, PhD, Y. Beguin MD, PhD, prof. F. Baron , E. Willems MD, PhD, C. Graux MD, PhD, T. Kerre MD, PhD, S. Servais MD, PhD
Acute graft-versus-host disease (aGVHD) remains a severe complication after allogeneic stem cell transplantation (alloHCT). It is a disregulated immune process, during which the immune cells of the donor attack the healthy tissues in the immunocompromised host. Over the past two decades, progress in understanding its pathophysiology have helped redefine aGVHD reactions and clinical presentations. Typically, the disease presents with serious inflammatory lesions mainly in the skin, gut and liver. Its severity is assessed by gathering clinical signs and dysfunctions of each organ. Despite standard prophylaxis regimens, aGVHD still occurs in approximately 30–60% of transplanted patients and remains a major cause of transplant-related morbidity and mortality. Hence, there is an urgent need for optimising preventive strategies. In this review, we give insights on how to make an accurate diagnosis and scoring assessment of aGVHD, propose a short overview of the current knowledge about its immunobiology and discuss the current and developing strategies for prevention.
(BELG J HEMATOL 2020;11(4):159–173)
Read moreBJH - volume 11, issue Abstract Book BHS, february 2020
G. Crochet MD, M. Bourgeois , E. Collinge MD, H. Vellemans MD, M. André MD, PhD, A. Sonet MD, C. Graux MD, PhD
BJH - volume 11, issue Abstract Book BHS, february 2020
S. Servais MD, PhD, prof. F. Baron , C. Lechanteur PhD, E. Baudoux MD, A. Briquet PhD, D. Selleslag MD, J. Maertens MD, PhD, X. Poiré MD, PhD, W. Schroyens MD, PhD, C. Graux MD, PhD, A. De Becker MD, R. Schots MD, PhD, P. Zachée MD, PhD, A. Ory , J. Herman , T. Kerre MD, PhD, Y. Beguin MD, PhD
BJH - 2018, issue Abstract Book BHS, february 2018
E. Collinge MD, C. Graux MD, PhD, M. André MD, PhD, H. Labussière-Wallet , M. Michallet , G. Salles
BJH - 2018, issue Abstract Book BHS, february 2018
H. Haguet , J. Douxfils PhD, PharmD, C. Chatelain MD, C. Graux MD, PhD, F. Mullier PhD, PharmD, J-M. Dogné PhD, PharmD
Top
